Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
VENTOLIN is a metered-dose inhaled aerosol containing albuterol (salbutamol), a rapid-acting beta-2 agonist bronchodilator. It is used to treat acute bronchospasm and as a rescue medication for patients with asthma and chronic obstructive pulmonary disease (COPD). The drug works by stimulating beta-2 adrenergic receptors in airway smooth muscle, causing rapid bronchodilation and relief of airway obstruction.
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30), the brand team is likely focused on cost management and defending market share rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma
Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants
A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) and SERETIDE™ (Fluticasone Propionate and Salmeterol) Given With VENTOLIN™ Mini-Spacer Compared to the Aerochamber Plus Spacer
A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler® and Ventolin® MDI in Stable Asthma Patients
Worked on VENTOLIN at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
VENTOLIN roles focus on market defense, pricing strategy, and cost management in a competitive generic-dominated environment. This product offers stable but limited growth opportunities, making it suitable for professionals building expertise in mature asset management and competitive dynamics rather than launch execution.